CA
NZ
UK
AU
IND
US
Intuitive Surgical (NASDAQ: ISRG) is reshaping expectations for the healthcare sector as its shares hover about 27% below a $560 target. This discount, combined with a streak of earnings surprises, has drawn attention from investors seeking exposure to medical‑device growth.
The move, effective July 13, 2026, underscores the company’s focus on scaling its antibody discovery platform, which serves pharmaceutical and biotechnology partners. Analysts suggest the hire could signal accelerated growth in OmniAb’s contract research services, a segment increasingly critical for drug development pipelines.
Aethlon Medical Inc. (NASDAQ: AEMD) disclosed new data from its ongoing cancer study, triggering a pre-market rally in its stock. The update highlights early but repeatable immune and tumor-signal shifts observed in the second cohort of participants, reinforcing investor interest in the company’s experimental …
The recent health update from Senator Mitch McConnell has brought attention to the US healthcare sector, as the senator recovers from pneumonia after a fall. This development may impact the sector, particularly in terms of healthcare policy and legislation. The healthcare industry is closely …
Tactile Systems Technology Inc (NASDAQ: TCMD) announced a strategic partnership on July 13, 2026 to expand the reach of its MyoSleeve wearable compression device. The company will serve as the sole U.S.
A gene therapy developer recently shared early findings from a preclinical study assessing an experimental treatment for Alzheimer’s disease. The announcement focused on the effects of a single intravenous administration in a non-human primate model, providing initial insights into the therapy’s potential.
Ocugen (NASDAQ: OCGN) disclosed a binding term sheet that will enable the licensing of its OCU400 gene therapy, aimed at treating retinitis pigmentosa, across markets in the Middle East and North Africa. This step illustrates the company’s intent to broaden its global presence in …
Armata Pharmaceuticals advances its clinical pipeline with a regulatory green light for pediatric research. The company confirmed an agreement with U.S. Health authorities on a study plan for its investigational therapy targeting serious bacterial infections in children.
BiomX Inc. (NYSE American: PHGE) has taken steps to cancel 1,013,637 shares after identifying a violation of NYSE American’s listing requirements. The issue arose following the company’s recent acquisition activity, which fell under the exchange’s regulatory oversight. The shares in question were issued earlier …
Cue Biopharma (NASDAQ: CUE) announced a private placement that will add approximately $50.0 million to its balance sheet. Accredited investors, including notable asset managers, participated in the transaction.
Please wait processing your request...